IP Library › Granted Patent US 9,351,829
Granted Patent B2
US 9,351,829 · App. 13/297,192 · Granted May 31, 2016

Double cross-linkage process to enhance post-implantation bioprosthetic tissue durability

Inventors: Sophie M. Carpentier (Paris, FR); Alain F. Carpentier (Paris, FR)
Assignee: Edwards Lifesciences Corporation
A61F2/2415A61K35/34A61L27/3625A61L27/3687A61L2400/02A61L2430/20
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,351,829
App. No.
13/297,192
Granted
May 31, 2016
Kind
B2
Abstract

Bioprosthetic tissues and methods for making same, comprising fixing bioprosthetic implant tissue by treatment with 0.1 to 10 wt. % glutaraldehyde at elevated temperature, capping said fixed tissue by treatment with a diamine crosslinking agent, and treating said capped tissue with about 0.6 wt. % glutaraldehyde.

Claims (33)

1. A method for preparing bioprosthetic implant tissue, comprising:

fixing a biological tissue with glutaraldehyde,

exposing said fixed tissue to a polyetheramine cross-linking agent under reducing conditions,

treating said exposed tissue with glutaraldehyde, and

storing said treated tissue in a terminal sterilization solution or further subjecting said treated tissue to a glycerol treatment solution.

2. The method of claim 1 , wherein the fixing is conducted with 0.1 to 10 wt % concentration of glutaraldehyde at about 50° C. and pH 5.8 for 2 to 25 days.

3. The method of claim 1 , wherein the exposing step is conducted in the presence of a reducing agent.

4. The method of claim 3 , wherein the reducing agent is sodium borohydride.

5. The method of claim 1 , wherein the polyetheramine cross-linking agent is delivered in water or a buffer solution.

6. The method of claim 1 , wherein the polyetheramine cross-linking agent is at a concentration of 0.01M to 1M and the exposing is performed for a period of 1 hour to 7 days, at temperatures between 4° C. and 50° C., and at pH between 8 and 13.

7. The method of claim 6 , wherein the polyetheramine cross-linking agent is at a concentration of 0.1M, and the exposing is performed for 48 hrs, at a temperature of 37° C., and at a pH 11.7.

8. The method of claim 4 , wherein sodium borohydride is used as an adjunct to the polyetheramine cross-linking agent at a concentration between 0.05% and 1%, and the exposing is performed for a period of 1 hr to 3 days at a temperature between 4° C. and 40° C.

9. The method of claim 8 , wherein the sodium borohydride is at a concentration of 0.25% and the exposing is performed for a period of 24 h at a temperature of 37° C.

10. The method of claim 1 , wherein during the fixing step, the glutaraldehyde concentration is 0.6 to 10 wt. %, and the fixing is performed for 1 to 90 days, at a temperature from 37° C. to 75° C., at a pH of 5.4 to 6.8.

11. The method of claim 10 , wherein during the fixing step, the glutaraldehyde concentration is 5%, and the fixing is performed for a time of 18 days, at a temperature of 52±2.5° C., at a pH of 5.8.

12. The method of claim 1 , further comprising treating the fixed tissue in a surfactant solution thereby substantially eliminating phospholipids.

13. The method of claim 12 , wherein the surfactant solution contains formaldehyde, ethanol and polyoxyethylene 20 sorbitan monooleate.

14. The method of claim 1 , wherein said biological tissue is selected from the group consisting of bovine pericardium, porcine tissue, blood vessels, skin, dura mater, pericardium, small intestinal submucosa, tissue heart valves, ligaments, and tendons.

15. The method of claim 1 , wherein said biological tissue is a native valve treated and mounted as a whole valve.

16. The method of claim 1 , wherein the treated biological tissue is stored in the terminal sterilization solution and wherein the terminal sterilization solution is a glutaraldehyde solution of 0.1% to 0.6 wt. % concentration.

17. The method of claim 1 , wherein the treated biological tissue is further subjected to the glycerol treatment solution and stored dry.

18. The method of claim 17 , wherein the biological tissue is dehydrated after being further subjected to the glycerol treatment solution.

19. The method of claim 18 , wherein the dehydrated tissue is sterilized in ethylene oxide.

20. A method of preparing bioprosthetic implant tissue comprising:

fixing a biological tissue with at least 0.2 wt. % glutaraldehyde at pH 5-6.8 between 45°-75° C. for 1 to 90 days;

exposing said fixed tissue to a polyetheramine cross-linking agent followed by reduction of Schiff base with NaBH 4 ,

treating said exposed tissue with about 0.6 wt. % glutaraldehyde and then treating with a surfactant;

wherein the foregoing steps are performed while stirring.

21. The method of claim 20 , wherein the fixing is done at a temperature of 50° C. for 18 days.

22. The method of claim 20 , wherein the treating said tissue with about 0.6 wt. % glutaraldehyde is performed for at least 1 month.

23. The method of claim 20 , further comprising storing the tissue in 0.6% glutaraldehyde at 4° C. for at least 2 months after treating the tissue with the surfactant.

24. The method of claim 20 , further comprising treating the tissue with a glycerol solution after treating the tissue with the surfactant.

25. The method of claim 1 , wherein the fixing is performed before the exposing.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 16, 2012
From: CARPENTIER, SOPHIE; CARPENTIER, ALAIN F.
To: EDWARDS LIFESCIENCES CORPORATION
Reel/Frame 027715/0413 →
Continuity (2)
Provisional Application 61414726 · Nov 17, 2010
Related Publication 20120123557A1 · May 17, 2012